OBI Pharma granted patent approval for its 2nd Generation Active Immunotherapy Treatment by Taiwan and Australia

1.Date of occurrence of the event: 23 Nov 2016 2.Company name: OBI Pharma 3.Relationship to the Company (please enter “head office” or  “subsidiaries”): Head Office 4.Reciprocal shareholding ratios: N/A 5.Cause of occurrence: Company pipeline product OBI-833 was granted a product patent for its ” Vaccines with higher carbohydrate antigen density and novel saponin adjuvant.” Patent […]

This article is password protected.

To view the content, please enter your password in the field below